TNF and juvenile idiopathic arthritis: Around one-third of patients with juvenile idiopathic arthritis (JIA) fail to respond to first-line MTX or TNF therapy, with even fewer achieving ≥ American College of Rheumatology Pediatric 70% criteria for response (ACRpedi70).